Background Sorafenib is the most widely used first-line treatment for patients with advanced
hepatocellular carcinoma (HCC), but such treatment provides only limited survival benefits …

Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …

Sorafenib, a multi-targeted kinase inhibitor, is the current standard systemic treatment for
advanced hepatocellular carcinoma. Sorafenib has anti-angiogenic and anti-proliferative …

Sorafenib resistance is often developed and impedes the benefits of clinical therapy in
hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib …

Novel promising strategies for combination with sorafenib are urgently needed to enhance
its clinical benefit and overcome toxicity in hepatocellular carcinoma (HCC). the molecular …

Sorafenib, a multi-kinase inhibitor, has been approved for cancer treatment for decades,
especially hepatocellular carcinoma (HCC). Although sorafenib produced substantial …

BACKGROUND Sorafenib has been shown to reduce the extent of immunosuppression in
patients with hepatocellular carcinoma (HCC). The rationale of this investigation was to …

Sertraline and fluoxetine are the two most commonly used selective serotonin reuptake
inhibitors (SSRIs) in the treatment of depression. Accumulating evidence has revealed that …

Sorafenib is a specific adenosine triphosphate–competitive RAF inhibitor used as a first‐line
treatment of advanced hepatocellular carcinoma (HCC). However, the responses are …

Hepatocellular carcinoma (HCC) is a difficult to treat cancer characterized by poor tumor
immunity with only one approved systemic drug, sorafenib. If novel combination treatments …